# ZIMMER BIOMET HOLDINGS, INC. (ZBH) · Edgar & Edgarette company card

> Zimmer Biomet Holdings (ZBH) grew revenue 7.2% in FY2025 to $8.2 billion, operating margin 13.3% against a 11.0% median for orthopedic, prosthetic & surgical appliances & supplies, equity 55.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1136869 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ZBH) · [JSON](https://www.pops4.com/boards/company/ZBH.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8.2B |
| Revenue growth, 1 year | 7.2% |
| Revenue growth per year | 4.8% |
| Operating margin | 13.3% (prior year 16.7%) |
| Net margin | 8.6% |
| Operating cash flow | $1.7B |
| Capital spending | $225M |
| Free cash flow | $1.5B |
| Cash | $592M |
| Long-term debt | $7.5B |
| Total assets | $23.1B |
| Total equity | $12.7B |
| Equity ÷ assets | 55.0% |
| Return on equity | 5.6% |
| Dividend per share | $0.96 |
| Dividend years rising | 0 |

## Readings, computed from those figures

- Altman Z: 3.96 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.59 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $8.2B (FY2025), total debt $7.5B. Experience: revenue up 7.2% on the year, up 4.8% a year over 4 years; operating margin 13.3%, down from 16.7%. Soundness: equity 55.0% of assets, return on equity 5.6%, payout 27.0% of profit. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $7.9B and $9.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $7.4B to $10.0B. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, orthopedic, prosthetic & surgical appliances & supplies): operating margin 13.3% against a 11.0% median; growth 7.2% against 7.5%.

Range logged 2026-09-25, receipt 3d602c03414b3aea, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526385256/0001193125-26-385256-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526447203/0001193125-26-447203-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526446145/0001193125-26-446145-index.htm)
- 8-K · filed 2026-09-08 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526385256/0001193125-26-385256-index.htm)
- 8-K · filed 2026-08-05 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526335108/0001193125-26-335108-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526335044/0001193125-26-335044-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1136869/000119312526333761/0001193125-26-333761-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001136869.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1136869

## Cite

POPS4, Edgar & Edgarette: ZIMMER BIOMET HOLDINGS, INC. (ZBH) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/ZBH. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.